The rapid expansion of biotechnology research and biologics manufacturing is significantly increasing the importance of cell culture contamination testing across pharmaceutical and life science industries. Cell culture contamination can compromise experimental accuracy, reduce manufacturing efficiency, and create substantial regulatory and financial risks for laboratories and biopharmaceutical companies.

According to the Polaris Market Research report, the global Mycoplasma Testing Market was valued at USD 1.36 Billion in 2025 and is projected to reach USD 4.3 Billion by 2034, registering a CAGR of 13.50% during 2025–2034.

Cell culture contamination testing has become essential for ensuring the safety and reliability of biologics, vaccines, stem cell therapies, and gene therapies. Mycoplasma contamination is particularly concerning because these microorganisms can alter cell behavior and experimental outcomes without obvious visual indicators. As a result, routine contamination testing is now a standard requirement across pharmaceutical manufacturing and biomedical research environments.

The increasing adoption of cell-based therapies and regenerative medicine applications is one of the primary drivers supporting growth in the Mycoplasma Testing Market. Advanced therapies rely heavily on highly controlled cell culture environments to ensure therapeutic effectiveness and patient safety. Contamination events can lead to costly production delays, product recalls, and compromised clinical outcomes.

PCR technology dominated the market in 2024 because it provides rapid and highly sensitive detection capabilities for identifying mycoplasma contamination. Laboratories increasingly prefer PCR-based contamination testing because it delivers faster results compared to traditional culture-based methods, improving operational efficiency and reducing production downtime.

The pharmaceutical and biotechnology companies segment accounted for the largest market share due to increasing biologics manufacturing activities and strict regulatory quality requirements. Regulatory agencies continue enforcing rigorous contamination testing protocols for biologics production, vaccine manufacturing, and cell therapy development. Compliance with these standards is essential for maintaining product approval and market access.

Technological advancements are significantly improving contamination testing workflows. Automated laboratory systems, real-time PCR platforms, and advanced microbial detection assays are helping laboratories increase throughput, reduce manual intervention, and improve result accuracy. These innovations are particularly valuable for large-scale biologics manufacturing facilities that require continuous quality monitoring.

Read More @ https://www.polarismarketresearch.com/industry-analysis/mycoplasma-testing-market

Contract research organizations and contract manufacturing organizations are also driving demand for contamination testing services. As pharmaceutical companies increasingly outsource research and manufacturing activities, third-party service providers must implement robust contamination control procedures to meet client expectations and regulatory standards.

Research institutions and academic laboratories represent another important end-user segment within the Mycoplasma Testing Market. Biomedical researchers increasingly rely on contamination testing to ensure data integrity and reproducibility in scientific studies involving cell cultures and tissue models.

North America remained the leading regional market in 2024 due to advanced pharmaceutical infrastructure, strong biotechnology research capabilities, and growing biologics production activities. Europe also continues to experience strong market demand driven by expanding life science research and stringent regulatory frameworks. Asia Pacific is projected to witness rapid growth during the forecast period owing to increasing pharmaceutical manufacturing investments and expanding biotechnology research initiatives.

Major companies operating in the Mycoplasma Testing Market include Agilent Technologies, Inc., Eurofins Scientific, Norgen Biotek Corp., and Bio-Rad Laboratories, Inc.. These companies continue investing in advanced contamination detection technologies and laboratory automation solutions.

As cell-based therapies, biologics manufacturing, and biomedical research continue expanding globally, cell culture contamination testing is expected to remain a critical component of quality assurance and operational reliability within the growing Mycoplasma Testing Market.

More Trending Latest Reports By Polaris Market Research:

Data Center Solutions Market

Reconciliation Software Market

Racing Simulator Market

Veterinary Clinical Chemistry Diagnostics Market

Europe Neurology Clinical Trials Market

Dry Mouth Relief Market

Mammography Market

Bioethanol Market

Data Center Liquid Cooling Market